Oric Pharmaceuticals ORIC 深 沪
已收盘 12-19 16:00:00 美东时间
8.04
-0.045
-0.56%
华盛通- 最 高8.24
- 今 开8.16
- 成交量 556.70万股
- 最 低 7.975
- 昨 收 8.085
- 总市值 7.81亿
- 52周最高 14.93
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 3.8951
- 委 比 39.13%
- 总股本 9712.30万
- 历史最高 40.81
- 量 比 3.91
- 振 幅 3.28%
- 历史最低 2.36
- 每 手 1
- 风险率 2.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price target.
12-08 22:08
Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results
Oric Pharmaceuticals ( ($ORIC) ) has issued an update. On December 6, 2025, Ori...
12-08 19:52
ORIC Pharmaceuticals Announces Poster Presentation From Phase 1b Study Of Enozertinib At ESMO Asia Congress 2025
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data
12-01 21:06
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Wolfe Research Initiates Coverage On ORIC Pharmaceuticals with Peer Perform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Peer Perform rating.
11-19 01:23
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
Oric Pharmaceuticals Inc (ORIC) has disclosed a new risk, in the Employment / P...
11-16 14:01
